MiR-125b targets erythropoietin and its receptor and their expression correlates with metastatic potential and ERBB2/HER2 expression

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Ferracin, Manuela ^a   Bassi, Cristian ^a   Pedriali, Massimo ^a   Pagotto, Sara ^b   D'Abundo, Lucilla ^a   Zagatti, Barbara ^a   Corrà, Fabio ^a   Musa, Gentian ^a   Callegari, Elisa ^a   Lupini, Laura ^a   Volpato, Stefano ^a   Querzoli, Patrizia ^a   Negrini, Massimo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Breast cancer; ERBB2; Erythropoietin; MicroRNA; miR 125b

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; MICRORNA 125B;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL;

3' UNTRANSLATED REGIONS; BINDING SITES; BREAST NEOPLASMS; ERYTHROPOIETIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICRORNAS; MOLECULAR SEQUENCE ANNOTATION; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; RECEPTORS, ERYTHROPOIETIN; RNA INTERFERENCE;

EID: 84886150597     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-130     Document Type: Article

References (39)

1. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
2. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H, Nagino M, Takahashi T. Detailed characterization of a homozygously deleted region corresponding to a candidate tumor suppressor locus at 21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008, 47:810-818.
3. Gao W, Shen H, Liu L, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011, 137:557-566.
4. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer 2008, 123:1616-1622.
5. Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, et al. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene 2007, 26:7590-7595.
6. Guan Y, Yao H, Zheng Z, Qiu G, Sun K. MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer 2011, 128:2274-2283.
7. Huang L, Lin JX, Yu YH, Zhang MY, Wang HY, Zheng M. Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One 2012, 7:e33762.
8. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK. MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression. Oncogene 2013, 32:2984-2991.
9. Laneve P, Di Marcotullio L, Gioia U, Fiori ME, Ferretti E, Gulino A, Bozzoni I, Caffarelli E. The interplay between microRNAs and the neurotrophin receptor tropomyosin-related kinase C controls proliferation of human neuroblastoma cells. Proc Natl Acad Sci USA 2007, 104:7957-7962.
10. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010, 11:136-146.
11. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007, 120:1046-1054.
12. Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of microRNA-125a is associated with breast cancer. J Med Genet 2009, 46:358-360.
13. Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA 2010, 107:21558-21563.
14. Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 2010, 24:478-490.
15. Enomoto Y, Kitaura J, Hatakeyama K, Watanuki J, Akasaka T, Kato N, Shimanuki M, Nishimura K, Takahashi M, Taniwaki M, et al. Emu/miR-125b transgenic mice develop lethal B-cell malignancies. Leukemia 2011, 25:1849-1856.
16. Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, Rao DS, O'Connell RM, Baltimore D. Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A. Proc Natl Acad Sci USA 2012, 109:4233-4238.
17. Willimott S, Wagner SD. miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem 2012, 287:2608-2617.
18. Hofmann MH, Heinrich J, Radziwill G, Moelling K. A short hairpin DNA analogous to miR-125b inhibits C-Raf expression, proliferation, and survival of breast cancer cells. Mol Cancer Res 2009, 7:1635-1644.
19. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, Lodish HF, Lim B. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009, 23:862-876.
20. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007, 282:1479-1486.
21. Rajabi H, Jin C, Ahmad R, McClary C, Joshi MD, Kufe D. MUCIN 1 Oncoprotein expression is suppressed by the miR-125b ONCOMIR. Genes Cancer 2010, 1:62-68.
22. Cui F, Li X, Zhu X, Huang L, Huang Y, Mao C, Yan Q, Zhu J, Zhao W, Shi H. MiR-125b inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting phosphoinositide 3-kinase catalytic subunit delta. Cell Physiol Biochem 2012, 30:1310-1318.
23. Hannafon BN, Sebastiani P, De Las Morenas A, Lu J, Rosenberg CL. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Breast Cancer Res 2011, 13:R24.
24. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu QL, Zeng MS, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011, 71:3552-3562.
25. Smirnov DA, Cheung VG. ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am J Hum Genet 2008, 83:243-253.
26. Akhavantabasi S, Sapmaz A, Tuna S, Erson-Bensan AE. miR-125b targets ARID3B in breast cancer cells. Cell Struct Funct 2012, 37:27-38.
27. Saetrom P, Biesinger J, Li SM, Smith D, Thomas LF, Majzoub K, Rivas GE, Alluin J, Rossi JJ, Krontiris TG, et al. A risk variant in an miR-125b binding site in BMPR1B is associated with breast cancer pathogenesis. Cancer Res 2009, 69:7459-7465.
28. van Dongen S, Abreu-Goodger C, Enright AJ. Detecting microRNA binding and siRNA off-target effects from expression data. Nat Methods 2008, 5:1023-1025.
29. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 2010, 18:423-435.
30. Mrhalova M, Kodet R, Kalinova M, Hilska I. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number. Pathol Res Pract 2003, 199:453-461.
31. Kuesters S, Maurer M, Burger AM, Metz T, Fiebig HH. Correlation of ErbB2 gene status, mRNA and protein expression in a panel of >100 human tumor xenografts of different origin. Onkologie 2006, 29:249-256.
32. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990, 50:6701-6707.
33. Szenajch J, Wcislo G, Jeong JY, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells from clinic to bench - a critical review. Biochim Biophys Acta 1806, 2010:82-95.
34. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res 2006, 12:332-339.
35. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001, 61:3561-3565.
36. Gombos Z, Danihel L, Repiska V, Acs G, Furth E. Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role of hypoxia in tumorigenesis. Indian J Pathol Microbiol 2011, 54:273-278.
37. Larsson AM, Jirstrom K, Fredlund E, Nilsson S, Ryden L, Landberg G, Pahlman S. Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer. Clin Cancer Res 2009, 15:5552-5559.
38. Glud M, Rossing M, Hother C, Holst L, Hastrup N, Nielsen FC, Gniadecki R, Drzewiecki KT. Downregulation of miR-125b in metastatic cutaneous malignant melanoma. Melanoma Res 2010, 20:479-484.
39. Tuma RS. Cancer stem cell hypothesis and trastuzumab in HER2-negative tumors. J Natl Cancer Inst 2012, 104:968-969.